Bayer names Nelson Ambrogio as new head of Radiology business at pharmaceuticals division
Berlin: Bayer has announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will serve on the Pharmaceuticals Executive Committee and be based in Berlin, Germany. Gerd Krueger, who has led the Radiology unit for the past eight years, will work closely with him on a smooth transition before retiring from Bayer after more than forty years of service at the end of March 2024.
Nelson Ambrogio, most recently Senior Vice President and General Manager of Bayer’s Oncology Business in the United States, is a global healthcare leader with a career spanning more than 25 years with Bayer. Ambrogio started his career with Schering AG, which Bayer acquired in 2006, and has held commercial leadership roles of increasing responsibility across North and South America, Europe and Asia-Pacific. His broad experience also includes regional and global positions at Bayer’s headquarters. Nelson Ambrogio is married and has four children.
“Nelson Ambrogio is a highly accomplished healthcare executive recognized for an exceptional track record of developing and growing businesses by leading diverse teams around the world. His breadth of experience and strong leadership capabilities will be key in continuing to drive our Radiology Business forward,” said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company’s Pharmaceuticals Division. “I also want to sincerely thank Gerd Krueger for his dedicated service for the company and for his outstanding leadership in advancing our Radiology Unit to a business with industry-leading growth and profitability, that is driving innovation in its core business as well as in new areas such as Digital. I wish Gerd all the very best in his future endeavors.”
“As a leader in key Radiology segments and building on a deep medical expertise across a multitude of diagnostic and therapeutic areas, Bayer is driving innovation in medical imaging to address today’s healthcare challenges and advance patient care,” said Nelson Ambrogio. “I am excited to join this highly committed team at a time where new exciting paths are taken to deliver true value to radiologists and their teams for the benefit of patients.”
Read also: Bayer Eylea 8 mg gets Japanese marketing nod
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.